Covance Receives Highest Level of Phase I Accreditation
|View printer-friendly version||<< Back|
— Leeds clinic receives MHRA accreditation for providing highest level of clinical trial patient safety —
PRINCETON, NJ, July 30, 2009 — Covance Inc. today announced that it has received standard and supplementary accreditation for the conduct of clinical pharmacology in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA). This voluntary accreditation process provides clinical trial volunteers and sponsors with confidence that research facilities and studies meet the industry's highest safety standards.
This accreditation was awarded to Covance's clinical research unit in Leeds, United Kingdom, where the company conducts first-in-human studies, including trials requiring a review of risk factors by the Expert Advisory Group.
"Covance delivers the highest level of data quality and patient safety for first-in-human trials, which is confirmed by the MHRA accreditation," said Rob Aspbury, M.D., managing director, clinical research services, Covance. "As an industry leader in clinical pharmacology, Covance provides superior experience and expertise in study design and conduct to support today's increasingly complex first-in-human trials."
MHRA accreditation was introduced to ensure the highest level of patient safety for early clinical development by providing more information about trial facilities. The process includes formal routine inspections that provide additional scope and depth to existing procedures for good clinical practice inspections.
Covance's clinical pharmacology expertise includes full-time physicians, clinical pharmacologists, registered pharmacists and more than 30 Advanced Life Support (ALS) trained nurses. The industry leader in the conduct of clinical pharmacology studies, Covance offers more than 500 beds across nine Phase I clinics located in the United States, United Kingdom, and Switzerland.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance are registered service marks of Covance in the United States and other countries.